Stocks · News reference
The Chemours Company (NYSE:CC) (the "Company") today announced that, along with DuPont de Nemours, Inc. ("Dupont") and Corteva, Inc. ("Corteva"), it has entered into a settlement (the
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Chemours (NYSE:CC) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to our entire
UBS analyst Joshua Spector maintains Chemours (NYSE:CC) with a Neutral and lowers the price target from $18 to $16.
Chemours PFAS settlement lifts shares as the $455 million deal clarifies liabilities, payment timing and future escrow obligations.
On October 1, 2026, Corteva Inc. (NYSE:CTVA) completed the spin-off of its seed operating segment into Vylor Inc. (NYSE:VYLR) through a pro rata distribution to holders of record as of the close of business on September
Analysts upgraded NetApp, Humana, Corteva, Afya, with price-target changes for four stocks.